Literature DB >> 29311752

Computational Design and Synthesis of Novel Fluoro-Analogs of Combretastatins A-4 and A-1.

Yao Zong1, Christie Shea1, Katherine Maffucci1, Iwao Ojima1,2.   

Abstract

Combretastatin A-1 (CA-1) and combretastatin A-4 (CA-4) isolated from the African bush willow Combretum caffrum are highly potent tubulin polymerization inhibitors, possessing strong antitumor activities because of their vascular disrupting properties. Extensive SAR studies have been done for CA-4 analogs. Because of poor solubility, water-soluble prodrugs of CA-4 and CA-1 have been developed, which are currently in human clinical trials. Fluorine plays an important role in the current drug discovery and development due to its unique properties. Thus, several fluorine-containing analogs of CA-4/CA-1 have been studied. However, no analogs, which have a CF3O-, CF2HO- or CF3- group instead of the 4'-methoxy group in the B ring, have been investigated. Therefore, we set out to design and synthesize those novel fluoro-analogs of CA-4/CA-1. For the design of the new analogs, we took a structure-based design approach based on the X-ray crystal structure of colchicine-tubulin complex (PDB: 4O2B) and computational docking analysis using the AutoDock Vina program. A library of novel fluoro-analogs of CA-4/CA-1 was generated and their docking energy scores obtained. It was found that those novel fluoro-analogs exhibited better docking energy scores than CA-4/CA-1. Also, docking poses of all of these fluoro-analogs were virtually superimposable and very good fit to the colchine binding site. Among 15 compounds designed and analyzed, we have synthesized 5 compounds and evaluated their cytotoxicity against drug-sensitive and multidrug-resistant cancer cell lines. All fluoro-analogs exhibited strong cytotoxicity even against multidrug-resistant cell line. However, the critical activity of this class of compounds is its vascular disrupting activity. Thus, further biological evaluations are warranted for those novel fluoro-analogs of CA-4/CA-1.

Entities:  

Keywords:  Anticancer agent; Combretastatin A-4 and A-1; Fluoro-analog; In silico screening; Structure-activity relationship; Structure-based drug design; Vascular disrupting agent

Year:  2017        PMID: 29311752      PMCID: PMC5755605          DOI: 10.1016/j.jfluchem.2017.09.007

Source DB:  PubMed          Journal:  J Fluor Chem        ISSN: 0022-1139            Impact factor:   2.050


  19 in total

1.  Structural requirements for the interaction of combretastatins with tubulin: how important is the trimethoxy unit?

Authors:  Keira Gaukroger; John A Hadfield; Nicholas J Lawrence; Steven Nolan; Alan T McGown
Journal:  Org Biomol Chem       Date:  2003-09-07       Impact factor: 3.876

Review 2.  The polar hydrophobicity of fluorinated compounds.

Authors:  Justin C Biffinger; Hong Woo Kim; Stephen G DiMagno
Journal:  Chembiochem       Date:  2004-05-03       Impact factor: 3.164

3.  Antineoplastic agents. 509: synthesis of fluorcombstatin phosphate and related 3-halostilbenes(1).

Authors:  George R Pettit; Mathew D Minardi; Heidi J Rosenberg; Ernest Hamel; Michael C Bibby; Sandie W Martin; M Katherine Jung; Robin K Pettit; Timothy J Cuthbertson; Jean-Charles Chapuis
Journal:  J Nat Prod       Date:  2005-10       Impact factor: 4.050

4.  Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Jean-Yves Blay; Zsuzsanna Pápai; Anthony W Tolcher; Antoine Italiano; Didier Cupissol; Antonio López-Pousa; Sant P Chawla; Emmanuelle Bompas; Nada Babovic; Nicolas Penel; Nicolas Isambert; Arthur P Staddon; Esma Saâda-Bouzid; Armando Santoro; Fabio A Franke; Patrick Cohen; Solenn Le-Guennec; George D Demetri
Journal:  Lancet Oncol       Date:  2015-04-08       Impact factor: 41.316

Review 5.  A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P).

Authors:  Dietmar W Siemann; David J Chaplin; Patricia A Walicke
Journal:  Expert Opin Investig Drugs       Date:  2009-02       Impact factor: 6.206

6.  New colorimetric cytotoxicity assay for anticancer-drug screening.

Authors:  P Skehan; R Storeng; D Scudiero; A Monks; J McMahon; D Vistica; J T Warren; H Bokesch; S Kenney; M R Boyd
Journal:  J Natl Cancer Inst       Date:  1990-07-04       Impact factor: 13.506

Review 7.  Fluorine in pharmaceutical industry: fluorine-containing drugs introduced to the market in the last decade (2001-2011).

Authors:  Jiang Wang; María Sánchez-Roselló; José Luis Aceña; Carlos del Pozo; Alexander E Sorochinsky; Santos Fustero; Vadim A Soloshonok; Hong Liu
Journal:  Chem Rev       Date:  2013-12-03       Impact factor: 60.622

8.  Isolation, structure, and synthesis of combretastatins A-1 and B-1, potent new inhibitors of microtubule assembly, derived from Combretum caffrum.

Authors:  G R Pettit; S B Singh; M L Niven; E Hamel; J M Schmidt
Journal:  J Nat Prod       Date:  1987 Jan-Feb       Impact factor: 4.050

9.  Fluorinated colchicinoids: antitubulin and cytotoxic properties.

Authors:  I Ringel; D Jaffe; S Alerhand; O Boye; A Muzaffar; A Brossi
Journal:  J Med Chem       Date:  1991-11       Impact factor: 7.446

10.  The novel microtubule-destabilizing drug BAL27862 binds to the colchicine site of tubulin with distinct effects on microtubule organization.

Authors:  Andrea E Prota; Franck Danel; Felix Bachmann; Katja Bargsten; Rubén M Buey; Jens Pohlmann; Stefan Reinelt; Heidi Lane; Michel O Steinmetz
Journal:  J Mol Biol       Date:  2014-02-11       Impact factor: 6.151

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.